Metformin Explained

Pronounce:,
Tradename:Glucophage, others
Dailymedid:Metformin
Pregnancy Au:C
Pregnancy Au Comment:[1]
Routes Of Administration:By mouth
Class:Antidiabetic agent
Atc Prefix:A10
Atc Suffix:BA02
Atc Supplemental:Combinations:
Legal Au:S4
Legal Au Comment:[2]
Legal Ca:Rx-only
Legal Ca Comment:[3]
Legal Uk:POM
Legal Uk Comment:[4]
Legal Us:Rx-only
Legal Eu:Rx-only
Legal Eu Comment:[5]
Bioavailability:50–60%[6] [7]
Protein Bound:Minimal
Metabolism:Not by liver
Elimination Half-Life:4–8.7 hours
Excretion:Urine (90%)
Index2 Label:as HCl
Cas Number:657-24-9
Cas Number2:1115-70-4
Pubchem:4091
Pubchem2:14219
Iuphar Ligand:4779
Drugbank:DB00331
Drugbank2:DBSALT000114
Chemspiderid:3949
Chemspiderid2:13583
Unii:9100L32L2N
Unii2:786Z46389E
Kegg:D04966
Kegg2:D00944
Chebi:6801
Chebi2:6802
Chembl:1431
Chembl2:1703
Synonyms:N,N-dimethylbiguanide[8]
Iupac Name:N,N-Dimethylimidodicarbonimidic diamide
C:4
H:11
N:5
Smiles:CN(C)C(=N)N=C(N)N
Smiles2:Cl.CN(C)C(=N)NC(N)=N
Stdinchi:1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)
Stdinchi2:1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H
Stdinchikey:XZWYZXLIPXDOLR-UHFFFAOYSA-N
Stdinchikey2:OETHQSJEHLVLGH-UHFFFAOYSA-N
Density:1.3±0.1[9]

Metformin, sold under the brand name Glucophage, among others, is the main first-line medication for the treatment of type2 diabetes,[10] [11] [12] particularly in people who are overweight.[11] It is also used in the treatment of polycystic ovary syndrome. It is sometimes used as an off-label adjunct to lessen the risk of metabolic syndrome in people who take antipsychotics.[13] Metformin is not associated with weight gain[14] and is taken by mouth.

Metformin is generally well tolerated. Common adverse effects include diarrhea, nausea, and abdominal pain. It has a small risk of causing low blood sugar. High blood lactic acid level (acidosis) is a concern if the medication is used in overly large doses or prescribed in people with severe kidney problems.[15] [16] It also inhibits inflammation.[17] [18]

Metformin is a biguanide anti-hyperglycemic agent.[19] It works by decreasing glucose production in the liver, increasing the insulin sensitivity of body tissues,[19] and increasing GDF15 secretion, which reduces appetite and caloric intake.[20] [21] [22] [23]

Metformin was first described in scientific literature in 1922 by Emil Werner and James Bell.[24] French physician Jean Sterne began the study in humans in the 1950s. It was introduced as a medication in France in 1957. [25] Metformin is on the World Health Organization's List of Essential Medicines,[26] and is the most widely used medication for diabetes taken by mouth. It is available as a generic medication. In 2021, it was the second most commonly prescribed medication in the United States, with more than 91million prescriptions.[27] [28]

Medical uses

Metformin is used to lower the blood glucose in those with type2 diabetes. It is also used as a second-line agent for infertility in those with polycystic ovary syndrome.[29]

Type 2 diabetes

The American Diabetes Association and the American College of Physicians both recommend metformin as a first-line agent to treat type2 diabetes.[30] [31] [32] It is as effective as repaglinide and more effective than all other oral drugs for type2 diabetes.[33]

Efficacy

Treatment guidelines for major professional associations, including the European Association for the Study of Diabetes, the European Society for Cardiology, and the American Diabetes Association, describe evidence for the cardiovascular benefits of metformin as equivocal.[34] A 2020 Cochrane systematic review did not find enough evidence of reduction of cardiovascular mortality, non-fatal myocardial infarction or non-fatal stroke when comparing metformin monotherapy to other glucose-lowering drugs, behavior change interventions, placebo or no intervention.[35]

The use of metformin reduces body weight in people with type2 diabetes[20] [36] in contrast to sulfonylureas, which are associated with weight gain. Some evidence shows that metformin is associated with weight loss in obesity in the absence of diabetes.[37] [38] Metformin has a lower risk of hypoglycemia than the sulfonylureas, although hypoglycemia has uncommonly occurred during intense exercise, calorie deficit, or when used with other agents to lower blood glucose.[39] [40] Metformin modestly reduces low density lipoprotein and triglyceride levels.

In individuals with prediabetes, a 2019 systematic review comparing the effects of metformin with other interventions in the reduction of risk of developing type2 diabetes[41] found moderate-quality evidence that metformin reduced the risk of developing type2 diabetes when compared to diet and exercise or a placebo. However, when comparing metformin to intensive diet or exercise, moderate-quality evidence was found that metformin did not reduce risk of developing type2 diabetes and very low-quality evidence was found that adding metformin to intensive diet or exercise did not show any advantage or disadvantage in reducing risk of type2 diabetes when compared to intensive exercise and diet alone. The same review also found one suitable trial comparing the effects of metformin and sulfonylurea in reducing risk of developing type2 diabetes in prediabetic individuals, however this trial did not report any patient relevant outcomes.

Polycystic ovarian syndrome

In those with polycystic ovarian syndrome (PCOS), tentative evidence shows that metformin use increases the rate of live births.[42] This includes in those who have not been able to get pregnant with clomiphene.[43] Metformin does not appear to change the risk of miscarriage.[42] A number of other benefits have also been found both during pregnancy and in nonpregnant women with PCOS.[44] [45] In an updated Cochrane (2020) review on metformin versus placebo/no treatment before or during IVF/ICSI in women with PCOS no conclusive evidence of improved live birth rates was found.[46] In long GnRH-agonist protocols there was uncertainty in the evidence of improved live birth rates but there could be increases in clinical pregnancy rate. In short GnRH-antagonist protocols metformin may reduce live birth rates with uncertainty on its effect on clinical pregnancy rate. Metformin may result in a reduction of OHSS but could come with a greater frequency of side effects. There was uncertainty as to metformin's impact on miscarriage. The evidence does not support general use during pregnancy for improving maternal and infant outcomes in obese women.[47]

The United Kingdom's National Institute for Health and Clinical Excellence recommended in 2004 that women with PCOS and a body mass index above 25 be given metformin for anovulation and infertility when other therapies fail to produce results.[48] UK and international clinical practice guidelines do not recommend metformin as a first-line treatment[49] or do not recommend it at all, except for women with glucose intolerance.[50] The guidelines suggest clomiphene as the first medication option and emphasize lifestyle modification independently from medical treatment. Metformin treatment decreases the risk of developing type2 diabetes in women with PCOS who exhibited impaired glucose tolerance at baseline.[51]

Diabetes and pregnancy

A total review of metformin use during pregnancy compared to insulin alone found good short-term safety for both the mother and baby, but unclear long-term safety.[52] Several observational studies and randomized controlled trials found metformin to be as effective and safe as insulin for the management of gestational diabetes.[53] [54] Nonetheless, several concerns have been raised and evidence on the long-term safety of metformin for both mother and child is lacking.[55] Compared with insulin, women with gestational diabetes treated with metformin gain less weight and are less likely to develop pre‐eclampsia during pregnancy.[56] Babies born to women treated with metformin have less visceral fat, and this may make them less prone to insulin resistance in later life.[57] The use of metformin for gestational diabetes resulted in smaller babies compared to treatment with insulin. However, despite initially lower birth weight, children exposed to metformin during pregnancy had accelerated growth after birth, and were heavier by mid-childhood than those exposed to insulin during pregnancy. This pattern of initial low birth weight followed by catch-up growth that surpasses comparative children has been associated with long-term cardiometabolic disease.[58]

Weight change

Metformin use is typically associated with weight loss.[59] It appears to be safe and effective in counteracting the weight gain caused by the antipsychotic medications olanzapine and clozapine.[60] [61] [62] Although modest reversal of clozapine-associated weight gain is found with metformin, primary prevention of weight gain is more valuable.[63]

Use with insulin

Metformin may reduce the insulin requirement in type1 diabetes, albeit with an increased risk of hypoglycemia.[64]

Contraindications

Metformin is contraindicated in people with:

Adverse effects

The most common adverse effect of metformin is gastrointestinal irritation, including diarrhea, cramps, nausea, vomiting, and increased flatulence. Metformin is more commonly associated with gastrointestinal adverse effects than most other antidiabetic medications.[67] The most serious potential adverse effect of metformin is lactic acidosis; this complication is rare, and seems to be related to impaired liver or kidney function.[68] Metformin is not approved for use in those with severe kidney disease, but may still be used at lower doses in those with kidney problems.[69]

Gastrointestinal

Gastrointestinal upset can cause severe discomfort; it is most common when metformin is first administered, or when the dose is increased. The discomfort can often be avoided by beginning at a low dose (1.0 to 1.7 g/day) and increasing the dose gradually, but even with low doses, 5% of people may be unable to tolerate metformin.[70] Use of slow or extended-release preparations may improve tolerability.

Long-term use of metformin has been associated with increased homocysteine levels[71] and malabsorption of vitamin B12.[72] [73] Higher doses and prolonged use are associated with increased incidence of vitamin B12 deficiency,[74] and some researchers recommend screening or prevention strategies.[75]

Lactic acidosis

Lactic acidosis almost never occurs with metformin exposure during routine medical care.[76] Rates of metformin-associated lactic acidosis are about nine per 100,000 persons/year, which is similar to the background rate of lactic acidosis in the general population.[77] A systematic review concluded no data exists to definitively link metformin to lactic acidosis.[78]

Metformin is generally safe in people with mild to moderate chronic kidney disease, with proportional reduction of metformin dose according to severity of estimated glomerular filtration rate (eGFR) and with periodic assessment of kidney function, (e.g., periodic plasma creatinine measurement).[79] The US Food and Drug Administration (FDA) recommends avoiding the use of metformin in more severe chronic kidney disease, below the eGFR cutoff of 30 mL/minute/1.73 m2.[80] Lactate uptake by the liver is diminished with metformin use because lactate is a substrate for hepatic gluconeogenesis, a process that metformin inhibits. In healthy individuals, this slight excess is cleared by other mechanisms (including uptake by unimpaired kidneys), and no significant elevation in blood levels of lactate occurs.[81] Given severely impaired kidney function, clearance of metformin and lactate is reduced, increasing levels of both, and possibly causing lactic acid buildup. Because metformin decreases liver uptake of lactate, any condition that may precipitate lactic acidosis is a contraindication. Common causes include alcoholism (due to depletion of NAD+ stores), heart failure, and respiratory disease (due to inadequate tissue oxygenation); the most common cause is kidney disease.[82]

Metformin-associated lactate production may also take place in the large intestine, which could potentially contribute to lactic acidosis in those with risk factors.[83] The clinical significance of this is unknown, though, and the risk of metformin-associated lactic acidosis is most commonly attributed to decreased hepatic uptake rather than increased intestinal production.[84]

Overdose

The most common symptoms following an overdose include vomiting, diarrhea, abdominal pain, tachycardia, drowsiness, and rarely, hypoglycemia or hyperglycemia.[85] [86] Treatment of metformin overdose is generally supportive, as no specific antidote is known. Extracorporeal treatments are recommended in severe overdoses.[87] Due to metformin's low molecular weight and lack of plasma protein binding, these techniques have the benefit of removing metformin from the blood plasma, preventing further lactate overproduction.

Metformin may be quantified in blood, plasma, or serum to monitor therapy, confirm a diagnosis of poisoning, or to assist in a forensic death investigation. Blood or plasma metformin concentrations are usually in a range of 1–4 mg/L in persons receiving therapeutic doses, 40–120 mg/L in victims of acute overdosage, and 80–200 mg/L in fatalities. Chromatographic techniques are commonly employed.[88] [89]

The risk of metformin-associated lactic acidosis is also increased by a massive overdose of metformin, although even quite large doses are often not fatal.[90]

Interactions

The H2-receptor antagonist cimetidine causes an increase in the plasma concentration of metformin by reducing clearance of metformin by the kidneys;[91] both metformin and cimetidine are cleared from the body by tubular secretion, and both, particularly the cationic (positively charged) form of cimetidine, may compete for the same transport mechanism. A small double-blind, randomized study found the antibiotic cephalexin to also increase metformin concentrations by a similar mechanism;[92] theoretically, other cationic medications may produce the same effect.

Metformin also interacts with anticholinergic medications, due to their effect on gastric motility. Anticholinergic drugs reduce gastric motility, prolonging the time drugs spend in the gastrointestinal tract. This impairment may lead to more metformin being absorbed than without the presence of an anticholinergic drug, thereby increasing the concentration of metformin in the plasma and increasing the risk for adverse effects.[93]

Pharmacology

Mechanism of action

The molecular mechanism of metformin is not completely understood. Multiple potential mechanisms of action have been proposed: inhibition of the mitochondrial respiratory chain (complex I), activation of AMP-activated protein kinase (AMPK), inhibition of glucagon-induced elevation of cyclic adenosine monophosphate (cAMP) with reduced activation of protein kinase A (PKA), complex IV–mediated inhibition of the GPD2 variant of mitochondrial glycerol-3-phosphate dehydrogenase (thereby reducing glycerol-derived hepatic gluconeogenesis), and an effect on gut microbiota.[94] [95] [96]

Metformin exerts an anorexiant effect in most people, decreasing caloric intake. Metformin decreases gluconeogenesis (glucose production) in the liver.[97] Metformin inhibits basal secretion from the pituitary gland of growth hormone, adrenocorticotropic hormone, follicle stimulating hormone, and expression of proopiomelanocortin,[98] which in part accounts for its insulin-sensitizing effect with multiple actions on tissues including the liver, skeletal muscle, endothelium, adipose tissue, and the ovaries.[99] The average patient with type2 diabetes has three times the normal rate of gluconeogenesis; metformin treatment reduces this by over one-third.[100]

Activation of AMPK was required for metformin's inhibitory effect on liver glucose production.[101] AMPK is an enzyme that plays an important role in insulin signaling, whole-body energy balance, and the metabolism of glucose and fats.[102] AMPK activation is required for an increase in the expression of small heterodimer partner, which in turn inhibited the expression of the hepatic gluconeogenic genes phosphoenolpyruvate carboxykinase and glucose 6-phosphatase.[103] Metformin is frequently used in research along with AICA ribonucleotide as an AMPK agonist. The mechanism by which biguanides increase the activity of AMPK remains uncertain: metformin increases the concentration of cytosolic adenosine monophosphate (AMP) (as opposed to a change in total AMP or total AMP/adenosine triphosphate) which could activate AMPK allosterically at high levels;[104] a newer theory involves binding to PEN-2.[105] Metformin inhibits cyclic AMP production, blocking the action of glucagon, and thereby reducing fasting glucose levels.[106] Metformin also induces a profound shift in the faecal microbial community profile in diabetic mice, and this may contribute to its mode of action possibly through an effect on glucagon-like peptide-1 secretion.

In addition to suppressing hepatic glucose production, metformin increases insulin sensitivity, enhances peripheral glucose uptake (by inducing the phosphorylation of GLUT4 enhancer factor), decreases insulin-induced suppression of fatty acid oxidation,[107] and decreases the absorption of glucose from the gastrointestinal tract. Increased peripheral use of glucose may be due to improved insulin binding to insulin receptors.[108] The increase in insulin binding after metformin treatment has also been demonstrated in patients with type2 diabetes.[109]

AMPK probably also plays a role in increased peripheral insulin sensitivity, as metformin administration increases AMPK activity in skeletal muscle.[110] AMPK is known to cause GLUT4 deployment to the plasma membrane, resulting in insulin-independent glucose uptake.[111] Some metabolic actions of metformin do appear to occur by AMPK-independent mechanisms, however AMPK likely has a modest overall effect and its activity is not likely to directly decrease gluconeogenesis in the liver.

Metformin has indirect antiandrogenic effects in women with insulin resistance, such as those with PCOS, due to its beneficial effects on insulin sensitivity.[112] It may reduce testosterone levels in such women by as much as 50%. A Cochrane review, though, found that metformin was only slightly effective for decreasing androgen levels in women with PCOS.[113]

Metformin also has significant effects on the gut microbiome, such as its effect on increasing agmatine production by gut bacteria, but the relative importance of this mechanism compared to other mechanisms is uncertain.[114] [115] [116]

Due to its effect on GLUT4 and AMPK, metformin has been described as an exercise mimetic.[117] [118]

Pharmacokinetics

Metformin has an oral bioavailability of 50–60% under fasting conditions, and is absorbed slowly.[119] [120] Peak plasma concentrations (Cmax) are reached within 1–3 hours of taking immediate-release metformin and 4–8 hours with extended-release formulations. The plasma protein binding of metformin is negligible, as reflected by its very high apparent volume of distribution (300–1000 L after a single dose). Steady state is usually reached in 1–2 days.

Metformin has acid dissociation constant values (pKa) of 2.8 and 11.5, so it exists very largely as the hydrophilic cationic species at physiological pH values. The metformin pKa values make it a stronger base than most other basic medications with less than 0.01% nonionized in blood. Furthermore, the lipid solubility of the nonionized species is slight as shown by its low logP value (log(10) of the distribution coefficient of the nonionized form between octanol and water) of −1.43. These chemical parameters indicate low lipophilicity and, consequently, rapid passive diffusion of metformin through cell membranes is unlikely. As a result of its low lipid solubility it requires the transporter SLC22A1 in order for it to enter cells.[121] [122] The logP of metformin is less than that of phenformin (−0.84) because two methyl substituents on metformin impart lesser lipophilicity than the larger phenylethyl side chain in phenformin. More lipophilic derivatives of metformin are presently under investigation with the aim of producing prodrugs with superior oral absorption than metformin.[123]

Metformin is not metabolized. It is cleared from the body by tubular secretion and excreted unchanged in the urine; it is undetectable in blood plasma within 24 hours of a single oral dose. The average elimination half-life in plasma is 6.2 hours. Metformin is distributed to (and appears to accumulate in) red blood cells, with a much longer elimination half-life: 17.6 hours (reported as ranging from 18.5 to 31.5 hours in a single-dose study of nondiabetics).[124]

Some evidence indicates that liver concentrations of metformin in humans may be two to three times higher than plasma concentrations, due to portal vein absorption and first-pass uptake by the liver in oral administration.[125]

Chemistry

Metformin hydrochloride (1,1-dimethylbiguanide hydrochloride) is freely soluble in water, slightly soluble in ethanol, but almost insoluble in acetone, ether, or chloroform. The pKa of metformin is 12.4.[126] The usual synthesis of metformin, originally described in 1922, involves the one-pot reaction of dimethylamine hydrochloride and 2-cyanoguanidine over heat.[127]

According to the procedure described in the 1975 Aron patent,[128] and the Pharmaceutical Manufacturing Encyclopedia,[129] equimolar amounts of dimethylamine and 2-cyanoguanidine are dissolved in toluene with cooling to make a concentrated solution, and an equimolar amount of hydrogen chloride is slowly added. The mixture begins to boil on its own, and after cooling, metformin hydrochloride precipitates with a 96% yield.

Impurities

In December 2019, the US FDA announced that it learned that some metformin medicines manufactured outside the United States might contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA), classified as a probable human carcinogen, at low levels.[130] Health Canada announced that it was assessing NDMA levels in metformin.[131]

In February 2020, the FDA found NDMA levels in some tested metformin samples that did not exceed the acceptable daily intake.[132] [133]

In February 2020, Health Canada announced a recall of Apotex immediate-release metformin,[134] followed in March by recalls of Ranbaxy metformin[135] and in March by Jamp metformin.[136]

In May 2020, the FDA asked five companies to voluntarily recall their sustained-release metformin products.[137] [138] [139] [140] [141] [142] The five companies were not named, but they were revealed to be Amneal Pharmaceuticals, Actavis Pharma, Apotex Corp, Lupin Pharma, and Marksans Pharma Limited in a letter sent to Valisure, the pharmacy that had first alerted the FDA to this contaminant in metformin via a Citizen Petition.[143]

In June 2020, the FDA posted its laboratory results showing NDMA amounts in metformin products it tested. It found NDMA in certain lots of ER metformin, and is recommending companies recall lots with levels of NDMA above the acceptable intake limit of 96 nanograms per day. The FDA is also collaborating with international regulators to share testing results for metformin.[144]

In July 2020, Lupin Pharmaceuticals pulled all lots (batches) of metformin after discovering unacceptably high levels of NDMA in tested samples.[145]

In August 2020, Bayshore Pharmaceuticals recalled two lots of tablets.[146]

History

The biguanide class of antidiabetic medications, which also includes the withdrawn agents phenformin and buformin, originates from the plant Goat's rue (Galega officinalis) also known as Galega, French lilac, Italian fitch, Spanish sainfoin, Pestilenzkraut, or Professor-weed. (The plant should not be confused with plants in the genus Tephrosia which are highly toxic and sometimes also called Goat's rue.) Galega officinalis has been used in folk medicine for several centuries.[147] G. officinalis itself does not contain biguanide medications which are chemically synthesized compounds composed of two guanidine molecules and designed to be less toxic than the plant-derived parent compounds guanidine and galegine (isoamylene guanidine).[147]

Metformin was first described in the scientific literature in 1922, by Emil Werner and James Bell, as a product in the synthesis of N,N-dimethylguanidine.[148] In 1929, Slotta and Tschesche discovered its sugar-lowering action in rabbits, finding it the most potent biguanide analog they studied.[149] This result was ignored, as other guanidine analogs such as the synthalins, took over and were themselves soon overshadowed by insulin.[150]

Interest in metformin resumed at the end of the 1940s. In 1950, metformin, unlike some other similar compounds, was found not to decrease blood pressure and heart rate in animals.[151] That year, Filipino physician Eusebio Y. Garcia[152] used metformin (he named it Fluamine) to treat influenza; he noted the medication "lowered the blood sugar to minimum physiological limit" and was not toxic. Garcia believed metformin to have bacteriostatic, antiviral, antimalarial, antipyretic, and analgesic actions.[153] In a series of articles in 1954, Polish pharmacologist Janusz Supniewski[154] was unable to confirm most of these effects, including lowered blood sugar. Instead he observed antiviral effects in humans.[155] [156]

French diabetologist Jean Sterne studied the antihyperglycemic properties of galegine, an alkaloid isolated from G. officinalis, which is related in structure to metformin, and had seen brief use as an antidiabetic before the synthalins were developed.[157] Later, working at Laboratoires Aron in Paris, he was prompted by Garcia's report to reinvestigate the blood sugar-lowering activity of metformin and several biguanide analogs. Sterne was the first to try metformin on humans for the treatment of diabetes; he coined the name "Glucophage" (glucose eater) for the medication and published his results in 1957.

Metformin became available in the British National Formulary in 1958. It was sold in the UK by a small Aron subsidiary called Rona.[158]

Broad interest in metformin was not rekindled until the withdrawal of the other biguanides in the 1970s. Metformin was approved in Canada in 1972,[159] but did not receive approval by the U.S. Food and Drug Administration (FDA) for type2 diabetes until 1994.[160] Produced under license by Bristol-Myers Squibb, Glucophage was the first branded formulation of metformin to be marketed in the U.S., beginning on 3 March 1995.[161] Generic formulations are available in several countries, and metformin is believed to have become the world's most widely prescribed antidiabetic medication.

Society and culture

Environmental impact

Metformin and its major transformation product guanylurea are present in wastewater treatment plant effluents and regularly detected in surface waters. Guanylurea concentrations above 200 μg/L have been measured in the German river Erpe, which are amongst the highest reported for pharmaceutical transformation products in aquatic environments.[162]

Formulations

Metformin is the British Approved Name (BAN), the United States Adopted Name (USAN), and the International Nonproprietary Name (INN). It is sold under several brand names. Common brand names include Glucophage, Riomet, Fortamet, and Glumetza in the US.[163] In other areas of the world, there is also Obimet, Gluformin, Dianben, Diabex, Diaformin, Metsol, Siofor, Metfogamma and Glifor.[164] [165] There are several formulations of metformin available on the market, and all but the liquid form have generic equivalents.

Combination with other medications

When used for type2 diabetes, metformin is often prescribed in combination with other medications. Several medications are available as fixed-dose combinations, with the potential to reduce pill burden, decrease cost, and simplify administration.[166] [167]

=Rosiglitazone

=A combination of metformin and rosiglitazone was released in 2002, and sold as Avandamet by GlaxoSmithKline,[168] [169] or as a generic medication.[170] Formulations are 500/1, 500/2, 500/4, 1000/2, and 1000 mg/4 mg of metformin/rosiglitazone.

In 2009, it was the most popular metformin combination.[171]

In 2005, the stock of Avandamet was removed from the market, after inspections showed the factory where it was produced was violating good manufacturing practices.[172] The medication pair continued to be prescribed separately, and Avandamet was again available by the end of that year. A generic formulation of metformin/rosiglitazone from Teva received tentative approval from the FDA and reached the market in early 2012.[173]

However, following a meta-analysis in 2007, that linked the medication's use to an increased risk of heart attack,[174] concerns were raised over the safety of medicines containing rosiglitazone. In September 2010, the European Medicines Agency recommended that the medication be suspended from the European market because the benefits of rosiglitazone no longer outweighed the risks.[175] [176]

It was withdrawn from the market in the UK and India in 2010,[177] and in New Zealand and South Africa in 2011.[178] From November 2011 until November 2013 the FDA[179] did not allow rosiglitazone or metformin/rosiglitazone to be sold without a prescription; moreover, makers were required to notify patients of the risks associated with its use, and the drug had to be purchased by mail order through specified pharmacies.[180] [181]

In November 2013, the FDA lifted its earlier restrictions on rosiglitazone after reviewing the results of the 2009 RECORD clinical trial (a six-year, open-label randomized control trial), which failed to show elevated risk of heart attack or death associated with the medication.[182] [183] [184]

= Pioglitazone

=The combination of metformin and pioglitazone (Actoplus Met, Piomet, Politor, Glubrava) is available in the US and the European Union.[185] [186] [187] [188] [189]

DPP-4 inhibitors

Dipeptidyl peptidase-4 inhibitors inhibit dipeptidyl peptidase-4 and thus reduce glucagon and blood glucose levels.

DPP-4 inhibitors combined with metformin include a sitagliptin/metformin combination (Janumet),[190] [191] a saxagliptin/metformin combination (Kombiglyze XR, Komboglyze),[192] [193] and an alogliptin/metformin combination (Kazano, Vipdomet).[194] [195]

Linagliptin combined with metformin hydrochloride is sold under the brand name Jentadueto.[196] [197] [198] As of August 2021, linagliptin/metformin is available as a generic medicine in the US.[199]

SGLT-2 inhibitors

There are combinations of metformin with the SGLT-2 inhibitors dapagliflozin, empagliflozin, and canagliflozin.

Sulfonylureas

Sulfonylureas act by increasing insulin release from the beta cells in the pancreas.[200]

A 2019 systematic review suggested that there is limited evidence if the combined used of metformin with sulfonylurea compared to the combination of metformin plus another glucose-lowering intervention, provides benefit or harm in mortality, severe adverse events, macrovascular and microvascular complications.[201] Combined metformin and sulfonylurea therapy did appear to lead to higher risk of hypoglicaemia.

Metformin is available combined with the sulfonylureas glipizide (Metaglip) and glibenclamide (US: glyburide) (Glucovance). Generic formulations of metformin/glipizide and metformin/glibenclamide are available (the latter is more popular).[202]

Meglitinide

Meglitinides are similar to sulfonylureas, as they bind to beta cells in the pancreas, but differ by the site of binding to the intended receptor and the drugs' affinities to the receptor. As a result, they have a shorter duration of action compared to sulfonylureas, and require higher blood glucose levels to begin to secrete insulin. Both meglitinides, known as nateglinide and repanglinide, is sold in formulations combined with metformin. A repaglinide/metformin combination is sold as Prandimet, or as its generic equivalent.[203] [204]

Triple combination

The combination of metformin with dapagliflozen and saxagliptin is available in the United States as Qternmet XR.[205] [206]

The combination of metformin with pioglitazone and glibenclamide[207] is available in India as Accuglim-MP, Adglim MP, and Alnamet-GP; and in the Philippines as Tri-Senza.

The combination of metformin with pioglitazone and lipoic acid is available in Turkey as Pional.

Research

Metformin is a pleiotropic drug, with extensive off-target activity beyond its antidiabetic effect. Much of this has been attributed to its action on AMPK, although other mechanisms have been proposed.[208] [209] Metformin has been studied for its effects on multiple other conditions, including:

Aging and life extension

Metformin has received substantial interest as an agent that delays aging, possibly through similar mechanisms as its treatment of diabetes (insulin and carbohydrate regulation).[220] [221] It has been studied in animal models (C. elegans and crickets) for effects on aging.[222]

A 2017 review found that people with diabetes who were taking metformin had lower all-cause mortality. They also had reduced cancer and cardiovascular disease compared with those on other therapies. In people without diabetes, metformin does not appear to reduce the risk of cancer and cardiovascular disease.[223] Whether metformin may be helpful in extending life, even in otherwise healthy people, remains controversial; a 2021 review of the literature found it is likely to improve healthspan, i.e., the number of years spent in good health, rather than lifespan overall.[224]

Cancer

The potential anticancer effects of metformin are believed to be mediated through multiple pathways, particularly involving AMPK activation and IGF-1R modulation. Research has focused particularly on stomach cancer, with evidence of protective impact (reducing risk of cancer) and improving survival rates among patients in whom cancer has already developed.[225] Despite promising findings, evidence is still preliminary and there is no consensus on its preventive and therapeutic role.[226]

COVID-19

A study found a benefit using metformin to reduce the occurrence of long COVID.[227] [228] [229] [230]

It is unclear if there is a reduced risk of death using metformin to treat people with COVID-19.[231] [232] [233]

Neurological and neurodegenerative disorders

There has been extensive research into the potential neuroprotective effects of metformin in developmental and neurodegenerative diseases, including Alzheimer's disease and other dementias, Parkinson's disease, Huntington's disease, certain types of epilepsy, and fragile X syndrome, with mixed results.[234]

Preliminary studies have examined whether metformin can reduce the risk of Alzheimer's disease, and whether there is a correlation between type2 diabetes and risk of Alzheimer's disease.[235] [236]

While metformin may reduce body weight in persons with fragile X syndrome, whether it improves neurological or psychiatric symptoms is uncertain.[234]

Derivatives

A derivative HL156A, also known as IM156, is a potential new drug for medical use.[237] [238] [239] [240] [241] [242]

Further reading

External links

Notes and References

  1. Web site: Metformin Use During Pregnancy . Drugs.com . 10 September 2019 . 4 February 2020 . 16 April 2020 . https://web.archive.org/web/20200416182342/https://www.drugs.com/pregnancy/metformin.html . live .
  2. Web site: Metformin SANDOZ metformin hydrochloride 850mg tablet bottle (148270) . Therapeutic Goods Administration (TGA) . 27 May 2022 . 29 April 2023.
  3. Web site: Metformin Hydrochloride . Health Canada . 6 March 2023 . 6 March 2023 . https://web.archive.org/web/20230306055806/https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17104 . live .
  4. Web site: Glucophage 500 mg film coated tablets - Summary of Product Characteristics (SmPC) . (emc) . 25 October 2022 . 5 March 2023 . 20 June 2022 . https://web.archive.org/web/20220620110218/https://www.medicines.org.uk/emc/product/987/smpc . live .
  5. Web site: Metformin and metformin-containing medicines . European Medicines Agency (EMA) . 13 October 2016 . 10 June 2024 . 18 November 2023 . https://web.archive.org/web/20231118173723/https://www.ema.europa.eu/en/medicines/human/referrals/metformin-metformin-containing-medicines . live .
  6. Dunn CJ, Peters DH . Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus . Drugs . 49 . 5 . 721–49 . May 1995 . 7601013 . 10.2165/00003495-199549050-00007 .
  7. Hundal RS, Inzucchi SE . Metformin: new understandings, new uses . Drugs . 63 . 18 . 1879–94 . 2003 . 12930161 . 10.2165/00003495-200363180-00001 .
  8. Sirtori CR, Franceschini G, Galli-Kienle M, Cighetti G, Galli G, Bondioli A, Conti F . Disposition of metformin (N,N-dimethylbiguanide) in man . Clinical Pharmacology and Therapeutics . 24 . 6 . 683–93 . December 1978 . 710026 . 10.1002/cpt1978246683 . 24531910 .
  9. Web site: Metformin. www.chemsrc.com. 10 May 2018. 12 June 2017. https://web.archive.org/web/20170612212251/http://www.chemsrc.com/en/cas/657-24-9_889579.html. live.
  10. Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, Green J, Huang E, Isaacs D, Kahan S, Leon J, Lyons SK, Peters AL, Prahalad P, Reusch JE, Young-Hyman D . 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022 . Diabetes Care . 45 . Suppl 1 . S125–S143 . January 2022 . 34964831 . 10.2337/dc22-s009 . 245538347 . free . doi .
  11. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC . 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD . European Heart Journal . 41 . 2 . 255–323 . January 2020 . 31497854 . 10.1093/eurheartj/ehz486 . free . doi .
  12. Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S . Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis . Annals of Internal Medicine . 164 . 11 . 740–751 . June 2016 . 27088241 . 10.7326/M15-2650 . 32016657 .
  13. de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R . Metformin in prevention and treatment of antipsychotic-induced weight gain: a systematic review and meta-analysis . BMC Psychiatry . 16 . 1 . 341 . October 2016 . 27716110 . 5048618 . 10.1186/s12888-016-1049-5 . free . doi .
  14. November 2014 . Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects . Prescrire International . 23 . 154 . 269–272 . 25954799.
  15. Blumenberg A, Benabbas R, Sinert R, Jeng A, Wiener SW . Do Patients Die with or from Metformin-Associated Lactic Acidosis (MALA)? Systematic Review and Meta-analysis of pH and Lactate as Predictors of Mortality in MALA . Journal of Medical Toxicology . 16 . 2 . 222–229 . April 2020 . 31907741 . 7099117 . 10.1007/s13181-019-00755-6.
  16. Lipska KJ, Bailey CJ, Inzucchi SE . Use of metformin in the setting of mild-to-moderate renal insufficiency . Diabetes Care . 34 . 6 . 1431–7 . June 2011 . 21617112 . 3114336 . 10.2337/dc10-2361 .
  17. 10680465 . 2023 . The Role and Mechanism of Metformin in Inflammatory Diseases . Journal of Inflammation Research . 16 . 5545–5564 . 10.2147/JIR.S436147 . free . 38026260 . Lin H, Ao H, Guo G, Liu M .
  18. 25772174 . March 2015 . Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect . Endocrine, Metabolic & Immune Disorders Drug Targets . 15 . 3 . 196–205 . 10.2174/1871530315666150316124019 . Saisho Y .
  19. Web site: Metformin Hydrochloride. The American Society of Health-System Pharmacists. 2 January 2017. live. https://web.archive.org/web/20161224162245/https://www.drugs.com/monograph/metformin-hydrochloride.html. 24 December 2016.
  20. Coll AP, Chen M, Taskar P, Rimmington D, Patel S, Tadross JA, Cimino I, Yang M, Welsh P, Virtue S, Goldspink DA, Miedzybrodzka EL, Konopka AR, Esponda RR, Huang JT, Tung YC, Rodriguez-Cuenca S, Tomaz RA, Harding HP, Melvin A, Yeo GS, Preiss D, Vidal-Puig A, Vallier L, Nair KS, Wareham NJ, Ron D, Gribble FM, Reimann F, Sattar N, Savage DB, Allan BB, O'Rahilly S . GDF15 mediates the effects of metformin on body weight and energy balance . Nature . 578 . 7795 . 444–448 . February 2020 . 31875646 . 7234839 . 10.1038/s41586-019-1911-y .
  21. Day EA, Ford RJ, Smith BK, Mohammadi-Shemirani P, Morrow MR, Gutgesell RM, Lu R, Raphenya AR, Kabiri M, McArthur AG, McInnes N, Hess S, Paré G, Gerstein HC, Steinberg GR . Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss . Nature Metabolism . 1 . 12 . 1202–1208 . December 2019 . 32694673 . 10.1038/s42255-019-0146-4 . 213199603 .
  22. Pappachan JM, Viswanath AK . Medical Management of Diabesity: Do We Have Realistic Targets? . Current Diabetes Reports . 17 . 1 . 4 . January 2017 . 28101792 . 10.1007/s11892-017-0828-9 . 10289148 .
  23. LaMoia TE, Butrico GM, Kalpage HA, Goedeke L, Hubbard BT, Vatner DF, Gaspar RC, Zhang XM, Cline GW, Nakahara K, Woo S, Shimada A, Hüttemann M, Shulman GI . Metformin, phenformin, and galegine inhibit complex IV activity and reduce glycerol-derived gluconeogenesis . Proceedings of the National Academy of Sciences of the United States of America . 119 . 10 . e2122287119 . March 2022 . 35238637 . 8916010 . 10.1073/pnas.2122287119 . free . doi . 2022PNAS..11922287L .
  24. Book: Fischer J . Analogue-based Drug Discovery II. 2010. John Wiley & Sons. 978-3-527-63212-1. 49. live. https://web.archive.org/web/20170908185310/https://books.google.com/books?id=h2Kd8ci4Ln8C&pg=PA49. 8 September 2017.
  25. Book: Stargrove MB, Treasure J, McKee DL . Herb, nutrient, and drug interactions : clinical implications and therapeutic strategies. 2008. Mosby/Elsevier. St. Louis, Mo.. 978-0-323-02964-3. 217. live. https://web.archive.org/web/20170908185309/https://books.google.com/books?id=49kLK--eumEC&pg=PA217. 8 September 2017.
  26. Book: ((World Health Organization)) . World Health Organization model list of essential medicines: 21st list 2019 . 2019 . 10665/325771 . World Health Organization . World Health Organization . Geneva . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO . free .
  27. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 . 15 January 2024 . https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  28. Web site: Metformin - Drug Usage Statistics . ClinCalc . 14 January 2024 . 7 October 2021 . https://web.archive.org/web/20211007010110/https://clincalc.com/DrugStats/Drugs/Metformin . live .
  29. Lord JM, Flight IH, Norman RJ . Metformin in polycystic ovary syndrome: systematic review and meta-analysis . BMJ . 327 . 7421 . 951–3 . October 2003 . 14576245 . 259161 . 10.1136/bmj.327.7421.951 .
  30. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S . Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations . Annals of Internal Medicine . 154 . 9 . 602–13 . May 2011 . 21403054 . 3733115 . 10.7326/0003-4819-154-9-201105030-00336 .
  31. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR . Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) . Diabetes Care . 35 . 6 . 1364–79 . June 2012 . 22517736 . 3357214 . 10.2337/dc12-0413 .
  32. Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P . Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians . Annals of Internal Medicine . 156 . 3 . 218–31 . February 2012 . 22312141 . 10.7326/0003-4819-156-3-201202070-00011 . free . doi .
  33. Jia Y, Lao Y, Zhu H, Li N, Leung SW . Is metformin still the most efficacious first-line oral hypoglycaemic drug in treating type 2 diabetes? A network meta-analysis of randomized controlled trials . Obesity Reviews . 20 . 1 . 1–12 . January 2019 . 30230172 . 10.1111/obr.12753 . free . doi .
  34. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL . ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary . Diabetes & Vascular Disease Research . 11 . 3 . 133–73 . May 2014 . 24800783 . 10.1177/1479164114525548 . free . doi .
  35. Gnesin F, Thuesen AC, Kähler LK, Madsbad S, Hemmingsen B . Metformin monotherapy for adults with type 2 diabetes mellitus . The Cochrane Database of Systematic Reviews . 2020 . 6 . CD012906 . June 2020 . 32501595 . 7386876 . 10.1002/14651858.CD012906.pub2 . Cochrane Metabolic and Endocrine Disorders Group .
  36. Johansen K . Efficacy of metformin in the treatment of NIDDM. Meta-analysis . Diabetes Care . 22 . 1 . 33–7 . January 1999 . 10333900 . 10.2337/diacare.22.1.33 .
  37. Golay A . Metformin and body weight . International Journal of Obesity . 32 . 1 . 61–72 . January 2008 . 17653063 . 10.1038/sj.ijo.0803695 . free . doi .
  38. Mead E, Atkinson G, Richter B, Metzendorf MI, Baur L, Finer N, Corpeleijn E, O'Malley C, Ells LJ . Drug interventions for the treatment of obesity in children and adolescents . The Cochrane Database of Systematic Reviews . 11 . CD012436 . November 2016 . 11 . 27899001 . 6472619 . 10.1002/14651858.CD012436 . 10149/620651 .
  39. Book: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM . Pharmacotherapy: a pathophysiologic approach . McGraw-Hill . New York . 2005 . 978-0-07-141613-9 .
  40. Web site: Glucophage package insert . https://web.archive.org/web/20210829202157/https://dailymed.nlm.nih.gov/dailymed/index.cfm . 29 August 2021 . Princeton, NJ . Bristol-Myers Squibb Company . 2009 . DailyMed .
  41. Madsen KS, Chi Y, Metzendorf MI, Richter B, Hemmingsen B . Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus . The Cochrane Database of Systematic Reviews . 2019 . 12 . CD008558 . December 2019 . 31794067 . 6889926 . 10.1002/14651858.CD008558.pub2 . Cochrane Metabolic and Endocrine Disorders Group .
  42. Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH . Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility . The Cochrane Database of Systematic Reviews . 11 . CD003053 . November 2017 . 2 . 29183107 . 6486196 . 10.1002/14651858.CD003053.pub6 . Our updated review suggests that metformin alone may be beneficial over placebo for live birth, although the evidence quality was low. .
  43. Ghazeeri GS, Nassar AH, Younes Z, Awwad JT . Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview . Acta Obstetricia et Gynecologica Scandinavica . 91 . 6 . 658–78 . June 2012 . 22375613 . 10.1111/j.1600-0412.2012.01385.x . 41145972 . free . doi .
  44. Kumar P, Khan K . Effects of metformin use in pregnant patients with polycystic ovary syndrome . Journal of Human Reproductive Sciences . 5 . 2 . 166–9 . May 2012 . 23162354 . 3493830 . 10.4103/0974-1208.101012 . free . doi .
  45. Tay CT, Joham AE, Hiam DS, Gadalla MA, Pundir J, Thangaratinam S, Teede HJ, Moran LJ . Pharmacological and surgical treatment of nonreproductive outcomes in polycystic ovary syndrome: An overview of systematic reviews . Clinical Endocrinology . 89 . 5 . 535–553 . November 2018 . 29846959 . 10.1111/cen.13753 . free . doi . 10536/DRO/DU:30151483 . free .
  46. Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Macedo CR . Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome . The Cochrane Database of Systematic Reviews . 2020 . CD006105 . December 2020 . 12 . 33347618 . 10.1002/14651858.CD006105.pub4 . 8171384 .
  47. Dodd JM, Grivell RM, Deussen AR, Hague WM . Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes . The Cochrane Database of Systematic Reviews . 2018 . CD010564 . July 2018 . 7 . 30039871 . 6513233 . 10.1002/14651858.CD010564.pub2 .
  48. Book: National Collaborating Centre for Women's and Children's Health . Fertility: assessment and treatment for people with fertility problems . London . Royal College of Obstetricians and Gynaecologists . 2004 . 978-1-900364-97-3 . 58–59 . live . https://web.archive.org/web/20090711000422/http://www.nice.org.uk/nicemedia/pdf/CG011fullguideline.pdf . 11 July 2009 .
  49. Web site: Balen A . Metformin therapy for the management of infertility in women with polycystic ovary syndrome . Scientific Advisory Committee Opinion Paper 13 . Royal College of Obstetricians and Gynaecologists . December 2008 . 13 December 2009 . dead . https://www.webcitation.org/5m73m3kuM?url=http://www.rcog.org.uk/files/rcog-corp/uploaded-files/SAC13metformin-minorrevision.pdf . 18 December 2009 .
  50. The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group . Consensus on infertility treatment related to polycystic ovary syndrome . Human Reproduction . 23 . 3 . 462–77 . March 2008 . 18308833 . 10.1093/humrep/dem426 . free . doi .
  51. Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN . Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome . European Journal of Endocrinology . 162 . 2 . 193–212 . February 2010 . 19841045 . 10.1530/EJE-09-0733 . free . doi .
  52. Butalia S, Gutierrez L, Lodha A, Aitken E, Zakariasen A, Donovan L . Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis . Diabetic Medicine . 34 . 1 . 27–36 . January 2017 . 27150509 . 10.1111/dme.13150 . 3418227 .
  53. Nicholson W, Bolen S, Witkop CT, Neale D, Wilson L, Bass E . Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review . Obstetrics and Gynecology . 113 . 1 . 193–205 . January 2009 . 19104375 . 10.1097/AOG.0b013e318190a459 . 28115952 .
  54. Kitwitee P, Limwattananon S, Limwattananon C, Waleekachonlert O, Ratanachotpanich T, Phimphilai M, Nguyen TV, Pongchaiyakul C . Metformin for the treatment of gestational diabetes: An updated meta-analysis . Diabetes Research and Clinical Practice . 109 . 3 . 521–32 . September 2015 . 26117686 . 10.1016/j.diabres.2015.05.017 .
  55. Balsells M, García-Patterson A, Solà I, Roqué M, Gich I, Corcoy R . Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis . BMJ . 350 . h102 . January 2015 . 25609400 . 4301599 . 10.1136/bmj.h102 . Systematic Review & Meta-Analysis .
  56. Alqudah A, McKinley MC, McNally R, Graham U, Watson CJ, Lyons TJ, McClements L . Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis . Diabetic Medicine . 35 . 2 . 160–172 . February 2018 . 29044702 . 10.1111/dme.13523 . 40045912 . 10453/130987 . free .
  57. Sivalingam VN, Myers J, Nicholas S, Balen AH, Crosbie EJ . Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications . Human Reproduction Update . 20 . 6 . 853–68 . 2014 . 25013215 . 10.1093/humupd/dmu037 . free . doi .
  58. Tarry-Adkins JL, Aiken CE, Ozanne SE . Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: A systematic review and meta-analysis . PLOS Medicine . 16 . 8 . e1002848 . August 2019 . 31386659 . 6684046 . 10.1371/journal.pmed.1002848 . free . doi .
  59. Yerevanian A, Soukas AA . Metformin: Mechanisms in Human Obesity and Weight Loss . Current Obesity Reports . 8 . 2 . 156–164 . June 2019 . 30874963 . 6520185 . 10.1007/s13679-019-00335-3 .
  60. Choi YJ . Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis . TheScientificWorldJournal . 2015 . 970730 . 2015 . 25664341 . 4310265 . 10.1155/2015/970730 . free . doi .
  61. Praharaj SK, Jana AK, Goyal N, Sinha VK . Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis . British Journal of Clinical Pharmacology . 71 . 3 . 377–82 . March 2011 . 21284696 . 3045546 . 10.1111/j.1365-2125.2010.03783.x .
  62. Yu O, Lu M, Lai TK, Hahn M, Agarwal SM, O'Donoghue B, Ebdrup BH, Siskind D . Metformin co-commencement at time of antipsychotic initiation for attenuation of weight gain: a systematic review and meta-analysis . Therapeutic Advances in Psychopharmacology . 14 . 20451253241255476 . 2024 . 38827016 . 10.1177/20451253241255476 . free .
  63. Siskind DJ, Leung J, Russell AW, Wysoczanski D, Kisely S . Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis . PLOS ONE . 11 . 6 . e0156208 . 2016 . 27304831 . 4909277 . 10.1371/journal.pone.0156208 . 2016PLoSO..1156208S . free . doi .
  64. Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR . The use of metformin in type 1 diabetes: a systematic review of efficacy . Diabetologia . 53 . 5 . 809–20 . May 2010 . 20057994 . 10.1007/s00125-009-1636-9 . free . doi .
  65. Web site: 25 February 2019. Metformin: medicine to treat type 2 diabetes. 15 October 2020. National Health Service. 11 March 2021. https://web.archive.org/web/20210311215750/https://www.nhs.uk/medicines/metformin/. live.
  66. Web site: METFORMIN HYDROCHLORIDE. 15 October 2020. NICE. 10 June 2021. https://web.archive.org/web/20210610014142/https://www.nice.org.uk/bnf-uk-only. live.
  67. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL . Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus . Annals of Internal Medicine . 147 . 6 . 386–99 . September 2007 . 17638715 . 10.7326/0003-4819-147-6-200709180-00178 . free . doi .
  68. Khurana R, Malik IS . Metformin: safety in cardiac patients . Heart . 96 . 2 . 99–102 . January 2010 . 19564648 . 10.1136/hrt.2009.173773 . 9746741 .
  69. Heaf J . Metformin in chronic kidney disease: time for a rethink . Peritoneal Dialysis International . 34 . 4 . 353–7 . June 2014 . 24711640 . 4079480 . 10.3747/pdi.2013.00344 .
  70. Fujita Y, Inagaki N . Metformin: New Preparations and Nonglycemic Benefits . Current Diabetes Reports . 17 . 1 . 5 . January 2017 . 28116648 . 10.1007/s11892-017-0829-8 . 9277684 .
  71. Wulffelé MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, Donker AJ, Stehouwer CD . Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial . Journal of Internal Medicine . 254 . 5 . 455–63 . November 2003 . 14535967 . 10.1046/j.1365-2796.2003.01213.x . 12507226 . free . doi .
  72. Andrès E, Noel E, Goichot B . Metformin-associated vitamin B12 deficiency . Archives of Internal Medicine . 162 . 19 . 2251–2 . October 2002 . 10.1001/archinte.162.19.2251-a . 12390080 . Editor's Correspondence . 22 January 2024 . 10 June 2024 . https://web.archive.org/web/20240610053501/https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/213629 . live .
  73. Gilligan MA . Metformin and vitamin B12 deficiency . Archives of Internal Medicine . 162 . 4 . 484–5 . February 2002 . 10.1001/archinte.162.4.484 . 11863489 . Editor's Correspondence . 22 January 2024 . 1 December 2020 . https://web.archive.org/web/20201201214214/https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/211187 . live .
  74. de Jager J, Kooy A, Lehert P, Wulffelé MG, van der Kolk J, Bets D, Verburg J, Donker AJ, Stehouwer CD . Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial . BMJ . 340 . c2181 . May 2010 . 20488910 . 2874129 . 10.1136/bmj.c2181 .
  75. Ting RZ, Szeto CC, Chan MH, Ma KK, Chow KM . Risk factors of vitamin B(12) deficiency in patients receiving metformin . Archives of Internal Medicine . 166 . 18 . 1975–9 . October 2006 . 17030830 . 10.1001/archinte.166.18.1975 . free . doi .
  76. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B . Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes . Diabetologia . 52 . 1 . 17–30 . January 2009 . 18941734 . 10.1007/s00125-008-1157-y . free . doi .
  77. Stang M, Wysowski DK, Butler-Jones D . Incidence of lactic acidosis in metformin users . Diabetes Care . 22 . 6 . 925–7 . June 1999 . 10372243 . 10.2337/diacare.22.6.925 .
  78. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE . Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis . Archives of Internal Medicine . 163 . 21 . 2594–602 . November 2003 . 14638559 . 10.1001/archinte.163.21.2594 . free . doi .
  79. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK . Metformin in patients with type 2 diabetes and kidney disease: a systematic review . JAMA . 312 . 24 . 2668–75 . 2014 . 25536258 . 4427053 . 10.1001/jama.2014.15298 .
  80. Web site: FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function . U.S. Food and Drug Administration (FDA) . 21 December 2018 . 14 November 2017 . 25 May 2021 . https://web.archive.org/web/20210525210522/https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-warnings-regarding-use-diabetes-medicine-metformin-certain . live .
  81. Book: Maharani U . Papadakis MA, McPhee SJ . Chapter 27: Diabetes Mellitus & Hypoglycemia . Current Medical Diagnosis and Treatment 2010 . 49th . McGraw-Hill Medical . 2009 . 1092–93 . 978-0-07-162444-2 . registration .
  82. Book: Shu AD, Myers MG, Shoelson SE . Golan ED, Tashjian AH, Armstrong EJ, Galanter JM, Armstrong AW, Arnaout RA, Rose HS . Chapter 29: Pharmacology of the Endocrine Pancreas . Principles of pharmacology: the pathophysiologic basis of drug therapy . Lippincott, Williams & Wilkins . Philadelphia . 2005 . 540–41 . 978-0-7817-4678-6.
  83. Kirpichnikov D, McFarlane SI, Sowers JR . Metformin: an update . Annals of Internal Medicine . 137 . 1 . 25–33 . July 2002 . 12093242 . 10.7326/0003-4819-137-1-200207020-00009 . 9140541 .
  84. Book: Davis SN . Brunton L, Lazo J, Parker K . Goodman & Gilman's The Pharmacological Basis of Therapeutics . 11th . 2006 . . New York . 978-0-07-142280-2 . Chapter 60: Insulin, Oral Hypoglycemic Agents, and the Pharmacology of the Endocrine Pancreas. Goodman & Gilman's The Pharmacological Basis of Therapeutics .
  85. Forrester MB . Adult metformin ingestions reported to Texas poison control centers, 2000-2006 . Human & Experimental Toxicology . 27 . 7 . 575–83 . July 2008 . 18829734 . 10.1177/0960327108090589 . 2008HETox..27..575F . 5413561 . 10.1.1.1031.9486 .
  86. Suchard JR, Grotsky TA . Fatal metformin overdose presenting with progressive hyperglycemia . The Western Journal of Emergency Medicine . 9 . 3 . 160–4 . August 2008 . 19561734 . 2672258 .
  87. Calello DP, Liu KD, Wiegand TJ, Roberts DM, Lavergne V, Gosselin S, Hoffman RS, Nolin TD, Ghannoum M . Extracorporeal Treatment for Metformin Poisoning: Systematic Review and Recommendations From the Extracorporeal Treatments in Poisoning Workgroup . Critical Care Medicine . 43 . 8 . 1716–30 . August 2015 . 25860205 . 10.1097/CCM.0000000000001002 . 13861731 .
  88. Liu A, Coleman SP . Determination of metformin in human plasma using hydrophilic interaction liquid chromatography-tandem mass spectrometry . Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences . 877 . 29 . 3695–700 . November 2009 . 19783231 . 10.1016/j.jchromb.2009.09.020 .
  89. R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 939–940.
  90. Teale KF, Devine A, Stewart H, Harper NJ . July 1998 . The management of metformin overdose . Anaesthesia . 53 . 7 . 698–701 . 10.1046/j.1365-2044.1998.436-az0549.x . 9771180 . 45218798 . free . doi .
  91. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F . Paul Rolan . Reduction of metformin renal tubular secretion by cimetidine in man . British Journal of Clinical Pharmacology . 23 . 5 . 545–51 . May 1987 . 3593625 . 1386190 . 10.1111/j.1365-2125.1987.tb03090.x .
  92. Jayasagar G, Krishna Kumar M, Chandrasekhar K, Madhusudan Rao C, Madhusudan Rao Y . Effect of cephalexin on the pharmacokinetics of metformin in healthy human volunteers . Drug Metabolism and Drug Interactions . 19 . 1 . 41–8 . 2002 . 12222753 . 10.1515/dmdi.2002.19.1.41 . 26919498 .
  93. May M, Schindler C . Clinically and pharmacologically relevant interactions of antidiabetic drugs . Therapeutic Advances in Endocrinology and Metabolism . 7 . 2 . 69–83 . April 2016 . 27092232 . 4821002 . 10.1177/2042018816638050 .
  94. Rena G, Pearson ER, Sakamoto K . Molecular mechanism of action of metformin: old or new insights? . Diabetologia . 56 . 9 . 1898–906 . September 2013 . 23835523 . 3737434 . 10.1007/s00125-013-2991-0 .
  95. Burcelin R . The antidiabetic gutsy role of metformin uncovered? . Gut . 63 . 5 . 706–7 . May 2014 . 23840042 . 10.1136/gutjnl-2013-305370 . 42142919 .
  96. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, Prigaro BJ, Wood JL, Bhanot S, MacDonald MJ, Jurczak MJ, Camporez JP, Lee HY, Cline GW, Samuel VT, Kibbey RG, Shulman GI . Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase . Nature . 510 . 7506 . 542–6 . June 2014 . 24847880 . 4074244 . 10.1038/nature13270 . 2014Natur.510..542M .
  97. Triggle CR, Ding H . Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium . Acta Physiologica . 219 . 1 . 138–151 . January 2017 . 26680745 . 10.1111/apha.12644 . 312517 .
  98. Vázquez-Borrego MC, Fuentes-Fayos AC, Gahete MD, Castaño JP, Kineman RD, Luque RM . The Pituitary Gland is a Novel Major Site of Action of Metformin in Non-Human Primates: a Potential Path to Expand and Integrate Its Metabolic Actions . Cellular Physiology and Biochemistry . 49 . 4 . 1444–1459 . 2018 . 30205369 . 10.1159/000493448 . free . doi .
  99. Diamanti-Kandarakis E, Economou F, Palimeri S, Christakou C . Metformin in polycystic ovary syndrome . Annals of the New York Academy of Sciences . 1205 . 1 . 192–8 . September 2010 . 20840272 . 10.1111/j.1749-6632.2010.05679.x . 44203632 . 2010NYASA1205..192D .
  100. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI . Mechanism by which metformin reduces glucose production in type 2 diabetes . Diabetes . 49 . 12 . 2063–9 . December 2000 . 11118008 . 2995498 . 10.2337/diabetes.49.12.2063 .
  101. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE . Role of AMP-activated protein kinase in mechanism of metformin action . The Journal of Clinical Investigation . 108 . 8 . 1167–74 . October 2001 . 11602624 . 209533 . 10.1172/JCI13505 .
  102. Towler MC, Hardie DG . AMP-activated protein kinase in metabolic control and insulin signaling . Circulation Research . 100 . 3 . 328–41 . February 2007 . 17307971 . 10.1161/01.RES.0000256090.42690.05 . free . doi .
  103. Kim YD, Park KG, Lee YS, Park YY, Kim DK, Nedumaran B, Jang WG, Cho WJ, Ha J, Lee IK, Lee CH, Choi HS . Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP . Diabetes . 57 . 2 . 306–14 . February 2008 . 17909097 . 10.2337/db07-0381 . free . doi .
  104. Zhang L, He H, Balschi JA . Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration . American Journal of Physiology. Heart and Circulatory Physiology . 293 . 1 . H457-66 . July 2007 . 17369473 . 10.1152/ajpheart.00002.2007 .
  105. Ma T, Tian X, Zhang B, Li M, Wang Y, Yang C, Wu J, Wei X, Qu Q, Yu Y, Long S, Feng JW, Li C, Zhang C, Xie C, Wu Y, Xu Z, Chen J, Yu Y, Huang X, He Y, Yao L, Zhang L, Zhu M, Wang W, Wang ZC, Zhang M, Bao Y, Jia W, Lin SY, Ye Z, Piao HL, Deng X, Zhang CS, Lin SC . Low-dose metformin targets the lysosomal AMPK pathway through PEN2 . Nature . 603 . 7899 . 159–165 . March 2022 . 35197629 . 8891018 . 10.1038/s41586-022-04431-8 . free . doi . 2022Natur.603..159M .
  106. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ . Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP . Nature . 494 . 7436 . 256–60 . February 2013 . 23292513 . 3573218 . 10.1038/nature11808 . 2013Natur.494..256M .
  107. Collier CA, Bruce CR, Smith AC, Lopaschuk G, Dyck DJ . Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle . American Journal of Physiology. Endocrinology and Metabolism . 291 . 1 . E182-9 . July 2006 . 16478780 . 10.1152/ajpendo.00272.2005 .
  108. Bailey CJ, Turner RC . Metformin . The New England Journal of Medicine . 334 . 9 . 574–9 . February 1996 . 8569826 . 10.1056/NEJM199602293340906 .
  109. Fantus IG, Brosseau R . Mechanism of action of metformin: insulin receptor and postreceptor effects in vitro and in vivo . The Journal of Clinical Endocrinology and Metabolism . 63 . 4 . 898–905 . October 1986 . 3745404 . 10.1210/jcem-63-4-898 .
  110. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S, Moller DE, Thorell A, Goodyear LJ . Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes . Diabetes . 51 . 7 . 2074–2081 . July 2002 . 12086935 . 10.2337/diabetes.51.7.2074 . doi . free .
  111. Hardie DG, Ross FA, Hawley SA . AMPK: a nutrient and energy sensor that maintains energy homeostasis . Nature Reviews. Molecular Cell Biology . 13 . 4 . 251–262 . March 2012 . 22436748 . 5726489 . 10.1038/nrm3311 .
  112. Nikolakis G, Kyrgidis A, Zouboulis CC . Is There a Role for Antiandrogen Therapy for Hidradenitis Suppurativa? A Systematic Review of Published Data . American Journal of Clinical Dermatology . 20 . 4 . 503–513 . August 2019 . 31073704 . 10.1007/s40257-019-00442-w . 149443722 .
  113. Luque-Ramírez M, Nattero-Chávez L, Ortiz Flores AE, Escobar-Morreale HF . Combined oral contraceptives and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis . Human Reproduction Update . 24 . 2 . 225–241 . March 2018 . 29293982 . 10.1093/humupd/dmx039 . free . doi .
  114. Weersma RK, Zhernakova A, Fu J . Interaction between drugs and the gut microbiome . Gut . 69 . 8 . 1510–1519 . August 2020 . 32409589 . 7398478 . 10.1136/gutjnl-2019-320204 . free . doi .
  115. MacNeil LT, Schertzer JD, Steinberg GR . Bacteria transmit metformin-associated lifespan extension . Nature Reviews. Endocrinology . 16 . 1 . 9–10 . January 2020 . 31645681 . 10.1038/s41574-019-0278-3 . 204836737 .
  116. Jones GR, Molloy MP . Metformin, Microbiome and Protection Against Colorectal Cancer . Digestive Diseases and Sciences . June 2020 . 66 . 5 . 1409–1414 . 32533543 . 10.1007/s10620-020-06390-4 . 219607625 .
  117. Guerrieri D, Moon HY, van Praag H . Exercise in a Pill: The Latest on Exercise-Mimetics . Brain Plasticity . 2 . 2 . 153–169 . March 2017 . 29765854 . 5928571 . 10.3233/BPL-160043 .
  118. Boulé NG, Robert C, Bell GJ, Johnson ST, Bell RC, Lewanczuk RZ, Gabr RQ, Brocks DR . Metformin and exercise in type 2 diabetes: examining treatment modality interactions . Diabetes Care . 34 . 7 . 1469–1474 . July 2011 . 21602430 . 3120188 . 10.2337/dc10-2207 .
  119. Web site: Glucophage (metformin hydrochloride) tablets, for oral use; Glucophage XR (metformin hydrochloride) extended-release tablets, for oral use Initial U.S. Approval:1995 . DailyMed . 5 March 2023 . 6 March 2023 . https://web.archive.org/web/20230306042913/https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=453104 . live .
  120. Heller JB . Metformin overdose in dogs and cats . Veterinary Medicine . April . 2007 . 231–33 . dead . https://web.archive.org/web/20071023063354/http://www.aspca.org/site/DocServer/vetm0407_231-234.pdf?docID=11061 . 23 October 2007 .
  121. Rosilio C, Ben-Sahra I, Bost F, Peyron JF . Metformin: a metabolic disruptor and anti-diabetic drug to target human leukemia . Cancer Letters . 346 . 2 . 188–96 . May 2014 . 24462823 . 10.1016/j.canlet.2014.01.006 .
  122. Pryor R, Cabreiro F . Repurposing metformin: an old drug with new tricks in its binding pockets . The Biochemical Journal . 471 . 3 . 307–22 . November 2015 . 26475449 . 4613459 . 10.1042/bj20150497 .
  123. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM . Clinical pharmacokinetics of metformin . Clinical Pharmacokinetics . 50 . 2 . 81–98 . February 2011 . 21241070 . 10.2165/11534750-000000000-00000 . 1440441 .
  124. Robert F, Fendri S, Hary L, Lacroix C, Andréjak M, Lalau JD . Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects . Diabetes & Metabolism . 29 . 3 . 279–83 . June 2003 . 12909816 . 10.1016/s1262-3636(07)70037-x .
  125. LaMoia TE, Shulman GI . Cellular and Molecular Mechanisms of Metformin Action . Endocrine Reviews . 42 . 1 . 77–96 . January 2021 . 32897388 . 7846086 . 10.1210/endrev/bnaa023 .
  126. Book: 10.1002/0471266949.bmc198. Diabetes Drugs: Present and Emerging. Burger's Medicinal Chemistry and Drug Discovery. 2010. Tilley J, Grimsby J, Erickson S, Berthel S . 1–38. 978-0471266945.
  127. Shapiro SL, Parrino VA, Freedman L . Hypoglycemic Agents. I Chemical Properties of β-Phenethylbiguanide. A New Hypoglycemic Agent . . 81 . 9 . 1959 . 2220–25 . 10.1021/ja01518a052.
  128. Procédé de préparation de chlorhydrate de diméthylbiguanide . Patent FR 2322860. fr. 1975.
  129. Book: Pharmaceutical Manufacturing Encyclopedia (Sittig's Pharmaceutical Manufacturing Encyclopedia) . 3rd . 3 . William Andrew . Norwich, NY . 2007 . 2208 . 978-0-8155-1526-5.
  130. Web site: Statement from Janet Woodcock, M.D., director of FDA's Center for Drug Evaluation and Research, on impurities found in diabetes drugs outside the U.S. . U.S. Food and Drug Administration (FDA) . 5 December 2019 . 4 February 2020 . 18 January 2021 . https://web.archive.org/web/20210118085409/https://www.fda.gov/news-events/press-announcements/statement-janet-woodcock-md-director-fdas-center-drug-evaluation-and-research-impurities-found . live .
  131. Web site: Recalls and safety alerts . Health Canada evaluating NDMA in metformin drugs . 5 December 2019 . 4 February 2020 . 17 April 2020 . https://web.archive.org/web/20200417042128/https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/71831a-eng.php . live .
  132. Web site: Laboratory Tests - Metformin . U.S. Food and Drug Administration (FDA) . 3 February 2020 . 4 February 2020 . 25 February 2020 . https://web.archive.org/web/20200225004129/https://www.fda.gov/drugs/drug-safety-and-availability/laboratory-tests-metformin . live .
  133. Web site: FDA Updates and Press Announcements on NDMA in Metformin . U.S. Food and Drug Administration (FDA) . 4 February 2020 . 4 February 2020 . 25 February 2020 . https://web.archive.org/web/20200225004121/https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-metformin . live .
  134. Web site: APO-Metformin (2020-02-04) . Health Canada . 2 June 2020 . 4 February 2020 . 27 December 2020 . https://web.archive.org/web/20201227043036/https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/72281r-eng.php . live .
  135. Web site: Ranbaxy Metformin Product Recall (2020-02-26) . . 2 June 2020 . 26 February 2020 . 26 November 2020 . https://web.archive.org/web/20201126035657/https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/72455r-eng.php . live .
  136. Web site: Jamp-Metformin Product Recall (2020-03-10) . . 2 June 2020 . 10 March 2020 . 26 November 2020 . https://web.archive.org/web/20201126043337/https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/72565r-eng.php . live .
  137. FDA Alerts Patients and Health Care Professionals to Nitrosamine Impurity Findings in Certain Metformin Extended-Release Products . U.S. Food and Drug Administration (FDA) . 2 June 2020 . 28 May 2020 . 22 March 2021 . https://web.archive.org/web/20210322105358/https://www.fda.gov/news-events/press-announcements/fda-alerts-patients-and-health-care-professionals-nitrosamine-impurity-findings-certain-metformin . live .
  138. Web site: Questions and Answers: NDMA impurities in metformin products . U.S. Food and Drug Administration (FDA) . 28 May 2020 . 5 June 2020 . 2 March 2021 . https://web.archive.org/web/20210302090352/https://www.fda.gov/drugs/drug-safety-and-availability/questions-and-answers-ndma-impurities-metformin-products . live .
  139. Web site: Amneal Pharmaceuticals LLC Issues Voluntary Nationwide Recall of Metformin Hydrochloride Extended Release Tablets, USP, 500 mg and 750 mg, Due to Detection of N-Nitrosodimethylamine (NDMA) Impurity . U.S. Food and Drug Administration (FDA) . 29 May 2020 . 2 June 2020 . 16 January 2021 . https://web.archive.org/web/20210116131122/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/amneal-pharmaceuticals-llc-issues-voluntary-nationwide-recall-metformin-hydrochloride-extended . live .
  140. Web site: Apotex Corp. Issues Voluntary Nationwide Recall of Metformin Hydrochloride Extended-Release Tablets 500mg Due to the Detection of N-nitrosodimethylamine (NDMA) . U.S. Food and Drug Administration (FDA) . 27 May 2020 . 2 June 2020 . 4 March 2021 . https://web.archive.org/web/20210304023938/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/apotex-corp-issues-voluntary-nationwide-recall-metformin-hydrochloride-extended-release-tablets . live .
  141. Web site: Teva Pharmaceuticals USA, Inc. Initiates Voluntary Nationwide Recall of Metformin Hydrochloride Extended-Release Tablets USP 500 mg and 750 mg Due to Detection of N-Nitrosodimethylamine (NDMA) . U.S. Food and Drug Administration (FDA) . 2 June 2020 . 5 June 2020 . 21 January 2021 . https://web.archive.org/web/20210121160530/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/teva-pharmaceuticals-usa-inc-initiates-voluntary-nationwide-recall-metformin-hydrochloride-extended . live .
  142. Web site: Marksans Pharma Limited Issues Voluntary Nationwide Recall of Metformin Hydrochloride Extended-Release Tablets, USP 500mg, Due to the Detection of N-Nitrosodimethylamine (NDMA) . U.S. Food and Drug Administration (FDA) . 2 June 2020 . 5 June 2020 . 23 January 2021 . https://web.archive.org/web/20210123205407/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/marksans-pharma-limited-issues-voluntary-nationwide-recall-metformin-hydrochloride-extended-release . live .
  143. Web site: Cavazzoni P . Patrizia Cavazzoni . Re: Docket No. FDA-2020-P-0978 . U.S. Food and Drug Administration (FDA) . 2 June 2020 . 28 May 2020 . 8 February 2021 . https://web.archive.org/web/20210208080851/https://downloads.regulations.gov/FDA-2020-P-0978-0007/attachment_1.pdf . live .
  144. Web site: Laboratory Tests - Metformin . U.S. Food and Drug Administration (FDA) . 5 June 2020 . 5 June 2020 . 22 April 2021 . https://web.archive.org/web/20210422093108/https://www.fda.gov/drugs/drug-safety-and-availability/laboratory-tests-metformin . live .
  145. Lupin Pharmaceuticals Inc. Lupin Pharmaceuticals, Inc. Issues Voluntarily Nationwide Recall of Metformin Hydrochloride Extended-Release Tablets, 500mg and 1000mg Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity. 9 July 2020. PR Newswire. 9 June 2021. https://web.archive.org/web/20210609205427/https://www.prnewswire.com/news-releases/lupin-pharmaceuticals-inc-issues-voluntarily-nationwide-recall-of-metformin-hydrochloride-extended-release-tablets-500mg-and-1000mg-due-to-the-detection-of--n-nitrosodimethylamine-ndma-impurity-301089754.html. live.
  146. Web site: Bayshore Pharmaceuticals, LLC Issues Voluntary Nationwide Recall of Metformin Hydrochloride Extended-Release Tablets USP, 500 mg and 750 mg Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity . U.S. Food and Drug Administration (FDA) . 19 August 2020 . 25 August 2020 . 19 December 2020 . https://web.archive.org/web/20201219234633/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/bayshore-pharmaceuticals-llc-issues-voluntary-nationwide-recall-metformin-hydrochloride-extended . live .
  147. Witters LA . The blooming of the French lilac . The Journal of Clinical Investigation . 108 . 8 . 1105–7 . October 2001 . 11602616 . 209536 . 10.1172/JCI14178 .
  148. Werner E, Bell J . The preparation of methylguanidine, and of ββ-dimethylguanidine by the interaction of dicyandiamide, and methylammonium and dimethylammonium chlorides respectively . J. Chem. Soc., Trans. . 121 . 1790–95 . 1922 . 10.1039/CT9222101790 . 4 September 2020 . 8 June 2021 . https://web.archive.org/web/20210608133134/https://zenodo.org/record/1860743 . live .
  149. See Chemical Abstracts, v.23, 42772 (1929) Slotta KH, Tschesche R. Über Biguanide, II.: Die blutzucker-senkende Wirkung der Biguanide. Berichte der Deutschen Chemischen Gesellschaft (A and B Series). 62. 6. 1398–1405 . 1929 . 10.1002/cber.19290620605.
  150. Campbell IW . Metformin – life begins at 50: A symposium held on the occasion of the 43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam, the Netherlands, September 2007. The British Journal of Diabetes & Vascular Disease. 7. 5. 247–52 . September 2007. 10.1177/14746514070070051001 .
  151. Dawes GS, Mott JC . Circulatory and respiratory reflexes caused by aromatic guanidines . British Journal of Pharmacology and Chemotherapy . 5 . 1 . 65–76 . March 1950 . 15405470 . 1509951 . 10.1111/j.1476-5381.1950.tb00578.x .
  152. About Eusebio Y. Garcia, see: Web site: Search for DOST-NRCP Dr. Eusebio Y. Garcia Award . Carteciano J . 2005 . Philippines Department of Science and Technology . 5 December 2009 . dead . https://web.archive.org/web/20091024075832/http://sntpost.stii.dost.gov.ph/frames/aprtojun05/Search_for_DOST_NRCP_13to14.htm . 24 October 2009 .
  153. Quoted from Chemical Abstracts, v.45, 24828 (1951) Garcia EY . Flumamine, a new synthetic analgesic and anti-flu drug . Journal of the Philippine Medical Association . 26 . 7 . 287–93 . July 1950 . 14779282 .
  154. About Janusz Supniewski, see: Wołkow PP, Korbut R . Pharmacology at the Jagiellonian University in Kracow, short review of contribution to global science and cardiovascular research through 400 years of history . Journal of Physiology and Pharmacology . 57 . Suppl 1 . 119–136 . April 2006 . 16766803 . dead . 22 December 2009 . https://web.archive.org/web/20091024211218/http://www.jpp.krakow.pl/journal/archive/0406_s1/pdf/119_0406_s1_article.pdf . 24 October 2009 .
  155. See Chemical Abstracts, v. 52, 22272 (1958) Supniewski J, Chrusciel T . [N-dimethyl-di-guanide and its biological properties] . pl . Archivum Immunologiae et Therapiae Experimentalis . 2 . 1–15 . 1954 . 13269290 .
  156. Quoted from Chemical Abstracts, v.49, 74699 (1955) Supniewski J, Krupinska J . [Effect of biguanide derivatives on experimental cowpox in rabbits] . fr . Bulletin de l'Académie Polonaise des Sciences, Classe 3: Mathématique, Astronomie, Physique, Chimie, Géologie et Géographie . 2(Classe II) . 161–65 . 1954.
  157. Bailey CJ, Day C . Metformin: its botanical background . Practical Diabetes International . 21 . 3 . 115–17 . 2004 . 10.1002/pdi.606 . 208203689 . free .
  158. Hadden DR . Goat's rue - French lilac - Italian fitch - Spanish sainfoin: gallega officinalis and metformin: the Edinburgh connection . The Journal of the Royal College of Physicians of Edinburgh . 35 . 3 . 258–60 . October 2005 . 16402501 . 21 December 2009 . 25 October 2020 . https://web.archive.org/web/20201025214723/http://www.rcpe.ac.uk/journal/issue/journal_35_3/hadden_goats%20rue.pdf . live .
  159. Lucis OJ . The status of metformin in Canada . Canadian Medical Association Journal . 128 . 1 . 24–6 . January 1983 . 6847752 . 1874707 .
  160. FDA Approves New Diabetes Drug . 30 December 1994 . U.S. Food and Drug Administration (FDA) . 6 January 2007 . https://web.archive.org/web/20070929152824/https://www.fda.gov/bbs/topics/ANSWERS/ANS00627.html . 29 September 2007 . dead .
  161. Web site: Drug Approval Package: Glucophage (metformin) . U.S. Food and Drug Administration (FDA) . https://web.archive.org/web/20200205051949/https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf . 5 February 2020 . live . 8 January 2007.
  162. Posselt M, Jaeger A, Schaper JL, Radke M, Benskin JP . Determination of polar organic micropollutants in surface and pore water by high-resolution sampling-direct injection-ultra high performance liquid chromatography-tandem mass spectrometry . Environmental Science: Processes & Impacts . 20 . 12 . 1716–1727 . December 2018 . 30350841 . 10.1039/C8EM00390D . free . doi .
  163. Christofides EA . Practical Insights Into Improving Adherence to Metformin Therapy in Patients With Type 2 Diabetes . Clinical Diabetes . 37 . 3 . 234–241 . July 2019 . 31371854 . 6640881 . 10.2337/cd18-0063 .
  164. Kaushik D, Karnes RJ, Eisenberg MS, Rangel LJ, Carlson RE, Bergstralh EJ . Effect of metformin on prostate cancer outcomes after radical prostatectomy . Urologic Oncology . 32 . 1 . 43.e1–7 . January 2014 . 23810664 . 4006350 . 10.1016/j.urolonc.2013.05.005 .
  165. Web site: Metformin. 17 July 2020. Drugs.com. 28 November 2020. https://web.archive.org/web/20201128083113/https://www.drugs.com/international/Metformin.html. live.
  166. Bailey CJ, Day C . Fixed-dose single tablet antidiabetic combinations . Diabetes, Obesity & Metabolism . 11 . 6 . 527–33 . June 2009 . 19175373 . 10.1111/j.1463-1326.2008.00993.x . 6569131 .
  167. Sheehan MT . Current therapeutic options in type 2 diabetes mellitus: a practical approach . Clinical Medicine & Research . 1 . 3 . 189–200 . July 2003 . 15931309 . 1069045 . 10.3121/cmr.1.3.189 .
  168. Web site: Drug Approval Package: Avandamet (rosiglitazone maleate/metformin HCL) NDA #021410 . U.S. Food and Drug Administration (FDA) . 30 April 2003 . 10 June 2024 . 10 June 2024 . https://web.archive.org/web/20240610053501/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021410_avandamet.cfm . live .
  169. FDA Approves GlaxoSmithKline's Avandamet (rosiglitazone maleate and metformin HCl), The Latest Advancement in the Treatment of Type 2 Diabetes. GlaxoSmithKline. 12 October 2002. 27 December 2006. live. https://web.archive.org/web/20070121050431/http://www.docguide.com/news/content.nsf/news/8525697700573E1885256C4F0075B2B3. 21 January 2007.
  170. Web site: Drugs@FDA: FDA-Approved Drugs. 21 July 2020. U.S. Food and Drug Administration (FDA). 21 March 2021. https://web.archive.org/web/20210321033724/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077337. live.
  171. Web site: 2009 Top 200 branded drugs by total prescriptions . dead . https://web.archive.org/web/20110714111215/http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/252010/674969/article.pdf . 14 July 2011 .  . Drug Topics (17 June 2010). Retrieved 2 September 2010.
  172. Questions and Answers about the Seizure of Paxil CR and Avandamet . U.S. Food and Drug Administration (FDA) . 4 March 2005 . 27 December 2006 . https://web.archive.org/web/20071014014507/https://www.fda.gov/oc/qanda/PaxilandAvandamet.html . 14 October 2007 . dead .
  173. Web site: Teva Pharm announces settlement of generic Avandia, Avandamet, and Avandaryl litigation with GlaxoSmithKline . Reuters . 27 September 2007 . 17 February 2009 . 3 May 2021 . https://web.archive.org/web/20210503040949/https://www.reuters.com/article/inPlayBriefing/idUSIN20070927170530TEVA20070927 . live .
  174. Nissen SE, Wolski K . Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes . The New England Journal of Medicine . 356 . 24 . 2457–71 . June 2007 . 17517853 . 10.1056/NEJMoa072761 . free . doi .
  175. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim . European Medicines Agency (EMA) . live . https://web.archive.org/web/20150924052044/http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fnews_and_events%2Fnews%2F2010%2F09%2Fnews_detail_001119.jsp&murl=menus%2Fnews_and_events%2Fnews_and_events.jsp&mid=WC0b01ac058004d5c1&jsenabled=false . 24 September 2015 . 23 September 2010 .
  176. News: Call to 'suspend' diabetes drug . . 23 September 2010 . live . https://web.archive.org/web/20100924044603/http://www.bbc.co.uk/news/health-11397645 . 24 September 2010 .
  177. Web site: Drugs banned in India . Central Drugs Standard Control Organization, Dte.GHS, Ministry of Health and Family Welfare, Government of India . 17 September 2013 . dead . https://web.archive.org/web/20150221053621/http://cdsco.nic.in/html/drugsbanned.html . 21 February 2015 .
  178. News: Diabetes drug withdrawn . 17 February 2011 . . . 5 November 2011 . 13 October 2013 . https://web.archive.org/web/20131013121141/http://www.stuff.co.nz/4669573 . dead .
  179. News: Controversial Diabetes Drug Harms Heart, U.S. Concludes . Harris G . . 19 February 2010 . live . https://web.archive.org/web/20170319173917/http://www.nytimes.com/2010/02/20/health/policy/20avandia.html . 19 March 2017 .
  180. Web site: Updated Risk Evaluation and Mitigation Strategy (REMS) . U.S. Food and Drug Administration (FDA) . 1 July 2021 . 6 March 2023 . 6 March 2023 . https://web.archive.org/web/20230306001836/https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-updated-risk-evaluation-and-mitigation-strategy-rems-restrict-access . live .
  181. Web site: FDA Drug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines . U.S. Food and Drug Administration (FDA) . 21 June 2019 . 6 March 2023 . 4 September 2022 . https://web.archive.org/web/20220904175732/https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-requires-removal-some-prescribing-and-dispensing-restrictions . live .
  182. News: Glaxo's Avandia Cleared From Sales Restrictions by FDA . Bloomberg . live . https://web.archive.org/web/20141109083451/http://www.bloomberg.com/news/2013-11-25/glaxo-s-avandia-cleared-from-sales-restrictions-by-fda.html . 9 November 2014 .
  183. FDA requires removal of certain restrictions on the diabetes drug Avandia . 25 November 2013 . U.S. Food and Drug Administration (FDA) . dead . https://web.archive.org/web/20150504051733/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm . 4 May 2015 .
  184. Web site: US agency reverses stance on controversial diabetes drug. live. https://web.archive.org/web/20151211005224/http://blogs.nature.com/news/2013/11/fda-reverses-stance-on-controversial-diabetes-drug.html. 11 December 2015.
  185. Web site: Glubrava EPAR . European Medicines Agency (EMA) . 17 September 2018 . 31 March 2020 . 9 June 2021 . https://web.archive.org/web/20210609205516/https://www.ema.europa.eu/en/medicines/human/EPAR/glubrava . live .
  186. Web site: Competact EPAR . European Medicines Agency (EMA) . 17 September 2018 . 31 March 2020 . 9 June 2021 . https://web.archive.org/web/20210609205507/https://www.ema.europa.eu/en/medicines/human/EPAR/competact . live .
  187. Web site: Pioglitazone (marketed as Actos, Actoplus Met, Duetact, and Oseni) Information . U.S. Food and Drug Administration (FDA) . 11 January 2017 . 31 March 2020 . 17 January 2021 . https://web.archive.org/web/20210117062857/https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/pioglitazone-marketed-actos-actoplus-met-duetact-and-oseni-information . live .
  188. Web site: FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function . U.S. Food and Drug Administration (FDA) . 3 April 2013 . 31 March 2020 . 25 May 2021 . https://web.archive.org/web/20210525210522/https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-warnings-regarding-use-diabetes-medicine-metformin-certain . live .
  189. Web site: FDA Drug Safety Communication: Updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer . U.S. Food and Drug Administration (FDA) . 4 August 2011 . 31 March 2020 . 26 January 2021 . https://web.archive.org/web/20210126071751/https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-updated-fda-review-concludes-use-type-2-diabetes-medicine-pioglitazone . live .
  190. Web site: Janumet- sitagliptin and metformin hydrochloride tablet, film coated . DailyMed . 12 August 2019 . 15 May 2020 . 9 June 2021 . https://web.archive.org/web/20210609205430/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d19c7ed0-ad5c-426e-b2df-722508f97d67 . live .
  191. Web site: Janumet EPAR . European Medicines Agency (EMA) . 17 September 2018 . 15 May 2020 . 9 June 2021 . https://web.archive.org/web/20210609205518/https://www.ema.europa.eu/en/medicines/human/EPAR/janumet . live .
  192. Web site: Kombiglyze XR- saxagliptin and metformin hydrochloride tablet, film coated, extended release . DailyMed . 24 October 2019 . 15 May 2020 . 25 September 2020 . https://web.archive.org/web/20200925063920/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fbd25da4-ebe6-45c9-beb8-93523d11a0b4 . live .
  193. Web site: Komboglyze EPAR . European Medicines Agency (EMA) . 17 September 2018 . 15 May 2020 . 30 October 2020 . https://web.archive.org/web/20201030073719/https://www.ema.europa.eu/en/medicines/human/EPAR/komboglyze . live .
  194. Web site: Kazano- alogliptin and metformin hydrochloride tablet, film coated . DailyMed . 14 June 2019 . 15 May 2020 . 9 June 2021 . https://web.archive.org/web/20210609205508/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83cb7914-a683-47bb-a713-f2bc6a596bd2 . live .
  195. Web site: Vipdomet EPAR . European Medicines Agency (EMA) . 17 September 2018 . 15 May 2020 . 9 June 2021 . https://web.archive.org/web/20210609205455/https://www.ema.europa.eu/en/medicines/human/EPAR/vipdomet . live .
  196. Web site: Jentadueto EPAR . European Medicines Agency (EMA) . 17 September 2018 . 31 March 2020 . 9 June 2021 . https://web.archive.org/web/20210609205529/https://www.ema.europa.eu/en/medicines/human/EPAR/jentadueto . live .
  197. Web site: Jentadueto- linagliptin and metformin hydrochloride tablet, film coated . DailyMed . 18 July 2019 . 31 March 2020 . 9 June 2021 . https://web.archive.org/web/20210609205429/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6dd9b86-0d18-95d4-2bc7-05591bfdd597 . live .
  198. Web site: Jentadueto XR- linagliptin and metformin hydrochloride tablet, film coated, extended release . DailyMed . 4 October 2021 . 5 October 2021 . https://web.archive.org/web/20211005014130/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d02a4d4-d312-80b4-05c4-691b8f0aa7aa . live .
  199. Web site: Linagliptin and Metformin Hydrochloride: FDA-Approved Drugs . U.S. Food and Drug Administration (FDA) . 24 September 2021 . 25 September 2021 . https://web.archive.org/web/20210925023954/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208336 . live .
  200. Grant JS, Graven LJ . Progressing From Metformin to Sulfonylureas or Meglitinides . en-US . Workplace Health & Safety . 64 . 9 . 433–9 . September 2016 . 27621259 . 10.1177/2165079916644263 . free . doi .
  201. Madsen KS, Kähler P, Kähler LK, Madsbad S, Gnesin F, Metzendorf MI, Richter B, Hemmingsen B . Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus . The Cochrane Database of Systematic Reviews . 4 . 4 . CD012368 . April 2019 . 30998259 . 6472662 . 10.1002/14651858.CD012368.pub2 . Cochrane Metabolic and Endocrine Disorders Group .
  202. Web site: The Use of Medicines in the United States: Review of 2010 . live . https://web.archive.org/web/20110422165905/http://www.imshealth.com/deployedfiles/imshealth/Global/Content/IMS%20Institute/Static%20File/IHII_UseOfMed_report.pdf . 22 April 2011 .  . IMS Institute for Healthcare Informatics (April 2011). Retrieved 28 April 2011.
  203. Web site: Drug Approval Package: PrandiMet (repaglinide/metformin HCI fixed-dose combination) NDA 22386. 21 July 2020. U.S. Food and Drug Administration (FDA). 21 July 2020. https://web.archive.org/web/20200721152208/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022386_prandimet_toc.cfm. live.
  204. Web site: Drugs@FDA: FDA-Approved Drugs. 21 July 2020. U.S. Food and Drug Administration (FDA) . 22 July 2020. https://web.archive.org/web/20200722002042/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200624. live.
  205. Web site: Drug Approval Package: Qternmet XR . U.S. Food and Drug Administration (FDA) . 27 January 2020 . 10 June 2024 . 17 February 2020 . https://web.archive.org/web/20200217083231/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210874Orig1s000TOC.cfm . live .
  206. Web site: Qternmet XR (dapagliflozin, saxagliptin, and metformin hydrochloride) extended-release tablets, for oral use Initial U.S. Approval: 2019 . DailyMed . 5 March 2023 . 6 March 2023 . https://web.archive.org/web/20230306042913/https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=567183 . live .
  207. Panikar V, Chandalia HB, Joshi SR, Fafadia A, Santvana C . Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy . The Journal of the Association of Physicians of India . 51 . 1061–4 . November 2003 . 15260389 . 22085315 .
  208. Dutta S, Shah RB, Singhal S, Dutta SB, Bansal S, Sinha S, Haque M . Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes . Drug Des Devel Ther . 17 . 1907–1932 . 2023 . 37397787 . 10312383 . 10.2147/DDDT.S409373 . free .
  209. Froldi G . View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences . Pharmaceuticals . 17 . 4 . April 2024 . 478 . 38675438 . 11054066 . 10.3390/ph17040478. free .
  210. Jalali M, Rahimlou M, Mahmoodi M, Moosavian SP, Symonds ME, Jalali R, Zare M, Imanieh MH, Stasi C . The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis: An up-to date systematic review and meta-analysis of randomized controlled trials . Pharmacological Research . 159 . 104799 . September 2020 . 32278041 . 10.1016/j.phrs.2020.104799 . 215741792 .
  211. Blazina I, Selph S . Diabetes drugs for nonalcoholic fatty liver disease: a systematic review . Systematic Reviews . 8 . 1 . 295 . November 2019 . 31783920 . 6884753 . 10.1186/s13643-019-1200-8 . free . doi .
  212. Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L . Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis . World Journal of Gastroenterology . 24 . 30 . 3361–3373 . August 2018 . 30122876 . 6092580 . 10.3748/wjg.v24.i30.3361 . free . doi .
  213. Ibáñez L, Ong K, Valls C, Marcos MV, Dunger DB, de Zegher F . Metformin treatment to prevent early puberty in girls with precocious pubarche . The Journal of Clinical Endocrinology and Metabolism . 91 . 8 . 2888–91 . August 2006 . 16684823 . 10.1210/jc.2006-0336 . free . doi .
  214. Ibáñez L, López-Bermejo A, Díaz M, Marcos MV, de Zegher F . Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence . The Journal of Clinical Endocrinology and Metabolism . 96 . 8 . E1262-7 . August 2011 . 21632811 . 10.1210/jc.2011-0555 . free . doi .
  215. Ibáñez L, Díaz R, López-Bermejo A, Marcos MV . Clinical spectrum of premature pubarche: links to metabolic syndrome and ovarian hyperandrogenism . Reviews in Endocrine & Metabolic Disorders . 10 . 1 . 63–76 . March 2009 . 18726694 . 10.1007/s11154-008-9096-y . 9129907 .
  216. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F . Metformin in cancer therapy: a new perspective for an old antidiabetic drug? . Molecular Cancer Therapeutics . 9 . 5 . 1092–9 . May 2010 . 20442309 . 10.1158/1535-7163.MCT-09-1186 . free . doi .
  217. Malek M, Aghili R, Emami Z, Khamseh ME . Risk of cancer in diabetes: the effect of metformin . ISRN Endocrinology . 2013 . 636927 . September 2013 . 24224094 . 3800579 . 10.1155/2013/636927 . free . doi .
  218. Campbell JM, Bellman SM, Stephenson MD, Lisy K . Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis . Ageing Research Reviews . 40 . 31–44 . November 2017 . 28802803 . 10.1016/j.arr.2017.08.003 . 20334490 .
  219. Soukas AA, Hao H, Wu L . Metformin as Anti-Aging Therapy: Is It for Everyone? . Trends in Endocrinology and Metabolism . 30 . 10 . 745–755 . October 2019 . 31405774 . 6779524 . 10.1016/j.tem.2019.07.015 .
  220. Novelle MG, Ali A, Diéguez C, Bernier M, de Cabo R . Metformin: A Hopeful Promise in Aging Research . Cold Spring Harbor Perspectives in Medicine . 6 . 3 . a025932 . March 2016 . 26931809 . 4772077 . 10.1101/cshperspect.a025932 .
  221. Kulkarni AS, Gubbi S, Barzilai N . Benefits of Metformin in Attenuating the Hallmarks of Aging . Cell Metabolism . 32 . 1 . 15–30 . July 2020 . 32333835 . 7347426 . 10.1016/j.cmet.2020.04.001 .
  222. Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA . Metformin as a Tool to Target Aging . Cell Metabolism . 23 . 6 . 1060–1065 . June 2016 . 27304507 . 5943638 . 10.1016/j.cmet.2016.05.011 .
  223. Lee CG, Heckman-Stoddard B, Dabelea D, Gadde KM, Ehrmann D, Ford L, Prorok P, Boyko EJ, Pi-Sunyer X, Wallia A, Knowler WC, Crandall JP, Temprosa M . Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study . Diabetes Care . 44 . 12 . 2775–2782 . December 2021 . 34697033 . 8669534 . 10.2337/dc21-1046 . free . doi .
  224. Mohammed I, Hollenberg MD, Ding H, Triggle CR . A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan . Frontiers in Endocrinology . 12 . 718942 . 2021 . 34421827 . 8374068 . 10.3389/fendo.2021.718942 . free . doi .
  225. Zhang J, Wen L, Zhou Q, He K, Teng L . Preventative and Therapeutic Effects of Metformin in Gastric Cancer: A New Contribution of an Old Friend . English . Cancer Management and Research . 12 . 8545–8554 . 16 September 2020 . 32982447 . 7505710 . 10.2147/CMAR.S264032 . free . doi .
  226. Web site: Sharma A . 29 October 2023 . The Role of Metformin in Gastric Cancer Treatment . 3 November 2023 . Witfire . en-US . 3 November 2023 . https://web.archive.org/web/20231103085807/https://thewitfire.in/2023/10/29/the-role-of-metformin-in-gastric-cancer-treatment/ . live .
  227. Bramante CT, Buse JB, Liebovitz DM, Nicklas JM, Puskarich MA, Cohen K, Belani HK, Anderson BJ, Huling JD, Tignanelli CJ, Thompson JL, Pullen M, Wirtz EL, Siegel LK, Proper JL, Odde DJ, Klatt NR, Sherwood NE, Lindberg SM, Karger AB, Beckman KB, Erickson SM, Fenno SL, Hartman KM, Rose MR, Mehta T, Patel B, Griffiths G, Bhat NS, Murray TA, Boulware DR . Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial . The Lancet. Infectious Diseases . 23 . 10 . 1119–1129 . October 2023 . 37302406 . 10.1016/S1473-3099(23)00299-2 . free . doi .
  228. Wise J . Covid-19: Metformin reduces the risk of developing long term symptoms by 40%, study finds . BMJ (Clinical Research Ed.) . 381 . 1306 . June 2023 . 37290779 . 10.1136/bmj.p1306 .
  229. Bramante CT, Huling JD, Tignanelli CJ, Buse JB, Liebovitz DM, Nicklas JM, Cohen K, Puskarich MA, Belani HK, Proper JL, Siegel LK, Klatt NR, Odde DJ, Luke DG, Anderson B, Karger AB, Ingraham NE, Hartman KM, Rao V, Hagen AA, Patel B, Fenno SL, Avula N, Reddy NV, Erickson SM, Lindberg S, Fricton R, Lee S, Zaman A, Saveraid HG, Tordsen WJ, Pullen MF, Biros M, Sherwood NE, Thompson JL, Boulware DR, Murray TA . Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19 . The New England Journal of Medicine . 387 . 7 . 599–610 . August 2022 . 36070710 . 9945922 . 10.1056/NEJMoa2201662 .
  230. COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) . ClinicalTrials.gov . 13 May 2024 . 9 June 2024 . 9 June 2024 . https://web.archive.org/web/20240609054010/https://classic.clinicaltrials.gov/ct2/show/NCT04510194 . live .
  231. Li Y, Yang X, Yan P, Sun T, Zeng Z, Li S . Metformin in Patients With COVID-19: A Systematic Review and Meta-Analysis . Frontiers in Medicine . 8 . 704666 . 2021 . 34490296 . 8416892 . 10.3389/fmed.2021.704666 . free .
  232. Ibrahim S, Lowe JR, Bramante CT, Shah S, Klatt NR, Sherwood N, Aronne L, Puskarich M, Tamariz L, Palacio A, Bomberg E, Usher M, King S, Benson B, Vojta D, Tignanelli C, Ingraham N . Metformin and Covid-19: Focused Review of Mechanisms and Current Literature Suggesting Benefit . Frontiers in Endocrinology . 12 . 587801 . 2021 . 34367059 . 8342037 . 10.3389/fendo.2021.587801 . free .
  233. Bramante CT, Ingraham NE, Murray TA, Marmor S, Hovertsen S, Gronski J, McNeil C, Feng R, Guzman G, Abdelwahab N, King S, Tamariz L, Meehan T, Pendleton KM, Benson B, Vojta D, Tignanelli CJ . Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis . The Lancet. Healthy Longevity . 2 . 1 . e34–e41 . January 2021 . 33521772 . 7832552 . 10.1016/S2666-7568(20)30033-7 .
  234. Gantois I, Popic J, Khoutorsky A, Sonenberg N . Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders . Annual Review of Medicine . 70 . 167–181 . January 2019 . 30365357 . 10.1146/annurev-med-081117-041238 . 53093694 . 9 October 2022 . 6 March 2023 . https://web.archive.org/web/20230306042913/https://escholarship.mcgill.ca/concern/articles/2j62s977h . live . free . doi .
  235. Campbell JM, Stephenson MD, de Courten B, Chapman I, Bellman SM, Aromataris E . Metformin Use Associated with Reduced Risk of Dementia in Patients with Diabetes: A Systematic Review and Meta-Analysis . Journal of Alzheimer's Disease . 65 . 4 . 1225–1236 . 2018 . 30149446 . 10.3233/jad-180263 . 6218120 .
  236. Campbell JM, Stephenson MD, de Courten B, Chapman I, Bellman SM, Aromataris E . Metformin and Alzheimer's disease, dementia and cognitive impairment: a systematic review protocol . JBI Database of Systematic Reviews and Implementation Reports . 15 . 8 . 2055–2059 . August 2017 . 28800055 . 10.11124/JBISRIR-2017-003380 .
  237. Lam TG, Jeong YS, Kim SA, Ahn SG . New metformin derivative HL156A prevents oral cancer progression by inhibiting the insulin-like growth factor/AKT/mammalian target of rapamycin pathways . Cancer Science . 109 . 3 . 699–709 . March 2018 . 29285837 . 5834796 . 10.1111/cas.13482 .
  238. Tsogbadrakh B, Ju KD, Lee J, Han M, Koh J, Yu Y, Lee H, Yu KS, Oh YK, Kim HJ, Ahn C, Oh KH . HL156A, a novel pharmacological agent with potent adenosine-monophosphate-activated protein kinase (AMPK) activator activity ameliorates renal fibrosis in a rat unilateral ureteral obstruction model . PLOS ONE . 13 . 8 . e0201692 . 2018 . 30161162 . 6116936 . 10.1371/journal.pone.0201692 . 2018PLoSO..1301692T . free . doi .
  239. Jeong YS, Lam TG, Jeong S, Ahn SG . Metformin Derivative HL156A Reverses Multidrug Resistance by Inhibiting HOXC6/ERK1/2 Signaling in Multidrug-Resistant Human Cancer Cells . Pharmaceuticals . 13 . 9 . 218 . August 2020 . 32872293 . 10.3390/ph13090218 . 7560051 . free . doi .
  240. Kim SA, Lam TG, Yook JI, Ahn SG . Antioxidant modifications induced by the new metformin derivative HL156A regulate metabolic reprogramming in SAMP1/kl (-/-) mice . Aging . 10 . 9 . 2338–2355 . September 2018 . 30222592 . 6188477 . 10.18632/aging.101549 .
  241. Choi J, Lee JH, Koh I, Shim JK, Park J, Jeon JY, Yun M, Kim SH, Yook JI, Kim EH, Chang JH, Kim SH, Huh YM, Lee SJ, Pollak M, Kim P, Kang SG, Cheong JH . Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A) . Oncotarget . 7 . 40 . 65643–65659 . October 2016 . 27582539 . 5323181 . 10.18632/oncotarget.11595 .
  242. Ju KD, Kim HJ, Tsogbadrakh B, Lee J, Ryu H, Cho EJ, Hwang YH, Kim K, Yang J, Ahn C, Oh KH . HL156A, a novel AMP-activated protein kinase activator, is protective against peritoneal fibrosis in an in vivo and in vitro model of peritoneal fibrosis . American Journal of Physiology. Renal Physiology . 310 . 5 . F342-50 . March 2016 . 26661649 . 10.1152/ajprenal.00204.2015 . free . doi .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Metformin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.